Letter to the editor: FLOUX-PMS study sample considerations

Abstract

Get full access to this article

View all access options for this article.

References

Cambron

Mostert

D’Hooghe

, et al. Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial. Mult Scler 2019; 25: 1728–1735.

Chataway

Weir

Fox

RJ.

The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials. Mult Scler 2019: 25: 1697–1699.

Bosma

Kragt

Brieva

, et al. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Mult Scler 2009; 15(6): 715–720.

Koch

Cutter

Giovannoni

, et al. Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set. Neurol Neuroimmunol Neuroinflamm 2017; 4: e358.

Grech

Butler

Stuckey

, et al. Neuroprotective benefits of antidepressants in multiple sclerosis: Are we missing the mark? J Neuropsychiatry Clin Neurosci. Epub ahead of print 3 April 2019. DOI: 10.1176/appi.neuropsych.18070164.